Breast

ARRS: How to manage 'controversial' high-risk breast lesions
By Amerigo Allegretto
Managing high-risk breast lesions with no consensus can be tricky, but breast radiologists can navigate this area.
April 30, 2025
Amie Lee, MD, presented at ARRS 2025 on managing 'controversial' high-risk breast lesions diagnosed on core needle biopsy. This slide outlines how to manage pleomorphic lobular carcinoma in situ (LCIS) via surgical excision.
Preop MRI fails to deliver results for breast cancer subtype
Preoperative MRI didn't improve outcomes in women with HER2-positive and hormone receptor-negative breast cancer in a new study.
April 29, 2025
Images show a palpable mass in the left breast in a 55-year-old woman. (A) Mammography shows a 26-mm ill-defined mass with fine linear calcifications in the central portion of the left breast (arrows). (B) ultrasound shows a 23-mm hypoechoic mass with calcifications in the corresponding area accompanying palpability (between the arrows). (C) An axial, fat-saturated, contrast-enhanced T1-weighted MRI scan shows an 18-mm irregular heterogeneous enhancing mass in the left breast (arrows). After breast-conserving surgery, the final pathologic report confirmed a grade II estrogen receptor–negative, progesterone receptor–negative, human epidermal growth factor receptor 2–positive invasive ductal carcinoma. There was no lymphovascular invasion, and the resection margins were clear. The patient declined both adjuvant chemotherapy and radiation therapy due to psychologic distress. (D) 11 months later, surveillance ultrasound helped to detect a new 25-mm irregular hypoechoic mass at the 12-o’clock position in the left breast (arrows). A subsequent ultrasound-guided biopsy confirmed it as a recurrence of grade II invasive ductal carcinoma, maintaining the same receptor statuses. Images courtesy of the RSNA.
iCAD partners with Microsoft on mammography suite integration
By AuntMinnie.com staff writers
iCAD will collaborate with Microsoft on incorporating a set of its AI-driven mammography tools into Microsoft’s Precision Imaging Network.
April 29, 2025
Breast Mammo Computer
ARRS: 'Report Cards' reduce BIRADS 3 usage
By Maryam Payne
"Report cards” were found to reduce rates of BI-RADS 3 assessment use, according to an award-winning poster presentation at ARRS 2025.
April 28, 2025
Breast Specialist Ultrasound Exam 400
Mammo uptake among veterans on par with nonveterans
By Amerigo Allegretto
Female veterans are as likely to undergo screening mammography as nonveteran women.
April 25, 2025
Mammogram Patient
ACS: Breast cancer screening rates have recovered post-COVID
By Kate Madden Yee
Rates of up-to-date breast cancer screening have recovered after declining during the COVID-19 pandemic.
April 23, 2025
Breast Screening Mammo
Ukrainian refugees at higher risk of advanced breast cancers
By Amerigo Allegretto
Displaced Ukrainian women have double the odds of having advanced-stage breast cancer compared with Polish citizens.
April 22, 2025
Ukrainian Flag
SNMMI Mars Shot Research Fund awards $100K fellowship
By AuntMinnie.com staff writers
The SNMMI Mars Shot Research Fund has bestowed its 2025 $100,000 research fellowship.
April 18, 2025
Snmmi
MRI radiomics model predicts risk in women with DCIS
By Will Morton
An MRI-based radiomics model shows potential for distinguishing low- from high-risk cases of ductal carcinoma in situ (DCIS), an early form of breast cancer.
April 1, 2025
Dcis Thumbnail
Do radiologists trust mammography AI software?
By Erik L. Ridley
A large-scale prospective trial exploring the use of mammography AI software in a breast cancer screening program has found that recalls were lower when cases were flagged by AI.
March 18, 2025
Full-field digital screening mammograms in participants recalled by the consensus discussion after being flagged by artificial intelligence (AI) computer-aided detection (CAD) but not by either of the two radiologists. (A) Mammogram with AI CAD score of 73 for a 55-year-old woman diagnosed with grade 3 in situ cancer and T1 (9-mm) invasive cancer in the left breast and lymph node metastasis. (B) Mammogram with AI CAD score of 54 for a 49-year-old woman diagnosed with grade 2 in situ cancer and T1 (6-mm) invasive cancer in the right breast and without lymph node metastasis. All images and caption courtesy of the RSNA.
Mammographic breast density not affected by multivitamins
By AuntMinnie.com staff writers
The use of multivitamin supplements has no influence on mammographic breast density, researchers have reported.
March 17, 2025
Breast Mammo 400
FES-PET shows promise staging patients with low-grade breast cancer
By Will Morton
F-18 fluoroestradiol (FES) PET may improve staging of grade 1 or 2 estrogen receptor-positive breast cancer compared with F-18 FDG-PET.
March 4, 2025
Fes Pet2 Thumbnail
Page 1 of 571
Next Page